Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: MYSM1 inhibits human colorectal cancer tumorigenesis by activating miR-200 family members/CDH1 and blocking PI3K/AKT signaling

Fig. 2

The clinical value of MYSM1 in the diagnosis and prognosis of CRC was evaluated. A Left: Representative IHC of MYSM1 in 38 adjacent normal (N), 53 adenocarcinoma (T) and 33 lymph node metastatic carcinoma (M) tissues from the same tissue microarray. Right: Graphs showing the relative frequencies of the immunoreactivity scores of MYSM1 in 124 samples. Scale bars: 200 μm (low power), 50 μm (high power). B Left: Scatter plot of the immunoreactivity scores of MYSM1 in CRC samples from 80 adjacent normal tissues (N) and 100 carcinomas (T) in the same tissue microarray. Right: Graphs indicating the distribution of the immunoreactivity scores of MYSM1 in 180 samples. The data are shown as the means ± SDs (*P < 0.05). C Left: Representative IHC of MYSM1 in stage I-IV CRC samples from 98 CRC patients. Right: Graphs showing the relative frequencies of the immunoreactivity scores of MYSM1 in different stages of CRC. Scale bars: 50 μm. D Kaplan-Meier survival curve analysis of the OS of 100 CRC patients from the same tissue microarray. The P log-rank test was used to determine statistical significance. E Left: Representative IHC of MYSM1 in samples of different histological subtypes, including mucinous adenocarcinoma (MA), tubular adenocarcinoma (TA) and adenocarcinoma (A), from 99 CRC patients. Right: Graphs indicating the distribution of the immunoreactivity scores of MYSM1 in different histologic subtypes. Scale bars: 50 μm. F Schematic diagram summarizing our model for studying the suppressive effects of MYSM1 on the EMT process. The immunoreactivity scores were based on the following scale: absent (0), moderate (2–3), elevated (4–5) and strong (6–7)

Back to article page